Factory bottlenecks behind one of Reckitt's best-known disinfectant brands left North American sales in reverse and helped force a guidance cut, sending the shares down 4.9% on a weak day for the FTSE 100.

When demand outruns the factory

Guidance cuts are often blamed on cautious shoppers. Reckitt (LSE:RKT) pointed largely at its own production lines. In its third-quarter trading update on Tuesday 27 October 2026, the group said temporary manufacturing capacity constraints in North America had restricted supply of Lysol, its disinfectant brand. Chief executive Kris Licht said "temporary manufacturing constraints limited our ability to fully meet demand".

The consequences rippled through the numbers. North America revenue fell 1.3% on a like-for-like basis to £649m in the quarter, making it the only one of Reckitt's three regions to shrink. The group cut its full-year 2026 Core Reckitt like-for-like growth guidance to 3.5%–4.5% from 4%–5%, and the shares closed down 4.9% at 5,218p. That made Reckitt one of the heaviest weights on the FTSE 100, which lost 80.79 points to close at 10,686.54.

Why a capacity problem hits so directly

Manufacturing constraints are a particular kind of setback. In a normal slowdown, demand weakens and a company may respond with promotions or new products. In a capacity squeeze, demand is there but the product cannot be made or shipped fast enough. Retailers may run short on shelves, and shoppers who cannot find their usual brand may try an alternative. Sales that would otherwise have been booked simply do not happen in that period.

For a brand such as Lysol, the effect can be meaningful because disinfectant products are typically bought regularly and stocked widely. Any gap in availability can therefore show up quickly in reported revenue. There is also a secondary risk that consumers who switch during a shortage do not all return once supply normalises, which is why companies usually move quickly to restore output.

Reckitt said improvements were already under way and that it expects a recovery in the fourth quarter. The company also announced in September 2026 a North America investment programme of up to US$600m, signalling a broader commitment to the region's manufacturing and commercial footprint. Investment of that kind is generally intended to add resilience as well as capacity, so that a single bottleneck is less able to disrupt supply in future.

Timing is the crucial variable for investors. A recovery in the fourth quarter would mean the shortfall is confined largely to a single reporting period, allowing North America to return to growth comparisons that look cleaner in 2027. A slower fix, by contrast, would extend the drag into another quarter and could place further pressure on the trimmed full-year range. Because the company has already lowered its guidance once, the next update is likely to be judged on whether that revised range proves achievable.

Suppose a brand normally sells 100 units a week but a factory constraint limits supply to 90 units for 10 weeks. Lost sales would total 100 units (10 units × 10 weeks). If each unit sells for £5, the shortfall would be £500 of revenue (100 × £5). The figures are hypothetical and simply show how supply gaps translate into missed revenue.

Lysol was not the only issue

While Lysol dominated the explanation for North America, Reckitt flagged two other pressures. Growth in the vitamins, minerals and supplements category in China slowed, and Finish faced tougher competition in dishwashing. Household Care, the segment that includes Finish, recorded revenue down 1.5% at £513m.

Group-wide, Core Reckitt revenue was £2.69bn in the quarter, up 3.3% like for like, or 3.9% excluding Russia Hygiene. That missed the 3.6% the market had expected. Volumes rose just 0.1%, with price and mix contributing 3.2%. A supply constraint naturally depresses volumes, which helps explain why the unit figure was so subdued.

Interestingly, the Germ Protection segment – the natural home for disinfectants – still grew 6.0% to £892m, helped by double-digit growth at Harpic. That suggests the category as a whole remained healthy and that the Lysol problem was specific rather than structural. Intimate Wellness rose 6.4% to £405m and Self Care grew 2.2% to £880m. Elsewhere, Emerging Markets delivered 8.0% growth to £1.17bn, while Europe edged up 0.8% to £867m.

Profitability guidance held firm. Reckitt kept its adjusted operating margin range unchanged at 24.9%–25.6% for Core Reckitt and Mead Johnson combined, and maintained its medium-term target of 4%–5% like-for-like growth. Its £500m buyback, begun on 5 August, had reached about £90m by 23 October.

Investors appeared to focus on the guidance cut rather than the promised recovery. By early afternoon the shares were down 4.94% at 5,234p, and they closed at a similar level. Consumer staples are often prized for predictable growth, and a reduction in guidance – whatever its cause – can unsettle that perception.

The broader session compounded the mood. HSBC fell 5.4% after its results, BP and Shell slipped with oil prices, and the FTSE 100 underperformed European and US markets even as the FTSE 250 rose 0.9%. Investors were also positioning ahead of Chancellor John Healey's first Autumn Budget and the US Federal Reserve decision on Wednesday 28 October.

Key dates to watch

  • Wednesday 28 October 2026 – UK Autumn Budget and US Federal Reserve rate decision
  • Wednesday 28 October 2026 – Unilever Q3 trading statement
  • Thursday 29 October 2026 – Haleon Q3 trading statement
  • Thursday 19 November 2026 – Reckitt North America investor event at its New Jersey headquarters

The bottom line

Lysol's supply problems turned North America into a drag on Reckitt's third quarter, contributing to near-flat volumes, a growth figure below forecasts and a trimmed full-year outlook. The company describes the constraints as temporary, with improvements under way and recovery expected in the fourth quarter, backed by an investment programme of up to US$600m. Healthy growth in Germ Protection suggests demand for the category has held up. The North America investor event on 19 November, and fourth-quarter trading, should show whether the bottleneck has eased – a key question for Reckitt's standing within the FTSE 100.